Prof. Laurie deleve: Artificial Intelligence is Getting Closer and Closer to the Clinic of Liver Disease

This year's annual meeting of American Association for the Study of Liver Diseases (AASLD2021) has been held recently. The conference was full of highlights. In an interview with the media of Hepatology Digest, Prof. Laurie deleve - FAASLD KECK SCHOOL OF MEDICINE OF USC, LOS ANGELES, CA, gave a general introduction to some of the interesting areas and highlights of the conference, and also mentioned the research topic on the application of artificial intelligence in liver diseases. The following will bring the interview report of Prof. Laurie deleve and the selected research report on artificial intelligence in evaluating liver fibrosis.

 Laurie Deleve: This AASLD conference includes academic content on multiple topics. Among these content, what do you pay most attention to or think is the most valuable and promising for research? There are so many sessions this year that are advancing the science of liver disease that it is very difficult to narrow it down. We have seen advances in a wide swath of areas so I would not and could not pick out any one particular area. However, to move us into the future with new research methods, I would draw attention to Meet the Expert Session 16 on Single Cell Analysis in Basic and Clinical Research, as well as the Clinical Research Workshop on the basics of navigating artificial intelligence in liver research. I would also highly recommend the Hans Popper State of the Art Lecture on Using Single Cell Genomics Approaches to Decode Human Liver Disease.  
In the field of disease, I can’t single out one, because the trio of NAFLD, alcohol associated liver disease and viral hepatitis are too important to overlook. We have not done disease-focused postgraduate courses in recent years. However, given the importance of alcohol and NAFLD, this year’s postgraduate course is specifically focused on fatty liver disease from both alcohol and metabolic syndrome. Research and MTEs on fatty liver disease are well represented throughout TLMdX and I highly encourage participation in these events. The elimination of viral hepatitis is a key focus of AASLD, and we devote programming to it at TLMdX, but it remains an important focus for AASLD year-round and we engage in many events and opportunities to move the science forward.